A simple blood test can now determine how well chemotherapy is working in Hodgkin lymphoma patients, a study has revealed.
Researchers found levels of a certain protein – CD163 – become elevated in Hodgkin lymphoma patients’ serum and drop as the tumour shrinks during chemotherapy.
The findings could lead to personalised treatments for patients suffering from the disease.
Read more at Queensland Institute of Medical Research